Pulmonary metastasectomy in uterine malignancies: outcome and prognostic factors
|
|
- Iris Gallagher
- 5 years ago
- Views:
Transcription
1 Original Article Pulmonary metastasectomy in uterine malignancies: outcome and prognostic factors Marco Anile, Sara Mantovani, Ylenia Pecoraro, Carolina Carillo, Lorenzo Gherzi, Andreina Pagini, Erino Angelo Rendina, Federico Venuta, Daniele Diso University of Rome Sapienza, Policlinico Umberto I Viale del Policlinico, Rome, Italy Contributions: (I) Conception and design: M Anile; (II) Administrative support: S Mantovani, Y Pecoraro; (III) Provision of study materials or patients: S Mantovani, A Pagini; (IV) Collection and assembly of data: C Carillo, L Gherzi; (V) Data analysis and interpretation: L Gherzi; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors Correspondence to: Marco Anile, MD. University of Rome Sapienza. Policlinico Umberto I Viale del Policlinico, Rome, Italy. marco.anile@uniroma1.it. Background: This retrospective study is designed to evaluate factors affecting survival in a population of patients receiving pulmonary metastasectomy after gynecologic cancers. Methods: Nineteen patients with isolated lung metastases (one or two) were surgically treated with R0 resection. Four of them underwent lobectomies. Results: Six patients (31.6%) received adjuvant therapy and 11 (58%) experienced recurrences after metastasectomy. Five- and ten-year survival were 40.9% and 31.4%, respectively. Five-year survival in patients receiving adjuvant therapy was 52.4%. At multivariate analysis factors negatively influencing survival were a disease-free interval (DFI) of less than 24 months and recurrence after pulmonary metastasectomy. Conclusions: Pulmonary resection for metastatic gynecologic cancer is feasible and effective; adequate selection of patients is mandatory to achieve satisfactory results and long-term survival. Keywords: Pulmonary metastasis; gynecologic cancer; survival Submitted Jun 09, Accepted for publication Jul 04, doi: /jtd View this article at: Introduction Uterine malignancies (UM) include different histologies with different behaviors and outcomes. Endometrial adenocarcinoma (EA) is the most frequent type followed by papillary serous adenocarcinoma (PSA) and uterine leiomyosarcoma (UL). According to Surveillance, Epidemiology, and End Results (SEER) (1) the percentage of new cases of endometrial cancer (EC) compared to all cancers every year is 3.6% with a rate of death equal to 1.8%. Squamous cell carcinoma (SCC) represents the most frequent cancer of the uterine cervix with an incidence of new cases every year of 0.8%. Most of UM show a good prognosis with a 5-year survival ranging between 65 80%; however, in a quarter of patients extrauterine disease statistically worsens long-term prognosis. The pattern of metastatic diffusion of UM is different between histologies; In fact EA and PSA commonly spread through the lymphatic pathway, whereas in UL and SCC hematogenous metastases are more frequent. The lung is the most common site of extrapelvic diffusion with an incidence ranging between 2.3% and 6.1% for EC and PSA (2-4); in patients with SCC and UL pulmonary recurrence occur in 10 20% and more than 60%, respectively (5-8). Pulmonary metastasectomy for UM was successfully performed in 1930 by Torek (9) and currently this procedure is recommended in selected patients when the primary tumor is controlled or controllable with no further extrapulmonary spread, complete resection is feasible and no better therapy is available. Survival after pulmonary metastasectomy varies in the literature and is affected by several prognostic factors as number of metastases, time of presentation after primary
2 S1274 Anile et al. Pulmonary metastasectomy after gynecologic cancers Table 1 Characteristics of patients underwent pulmonary metastasectomy Variables N (%) Age (mean ± standard deviation) 61.2±12.1 DFI (median months and range) 35 [12 87] Adjuvant CHT after gynecologic surgery, n (%) 5 (26.3) Histology Endometrial adenocarcinoma 12 (63.2) Uterine leiomyosarcoma 4 (21.0) Squamous cell carcinoma 2 (10.5) Papillary serous adenocarcinoma 1 (5.3) Surgical approach Uniportal VATS 9 (47.4) Biportal VATS 3 (15.8) Lateral thoracotomy 7 (36.8) Type of resection Single wedge resection 13 (68.4) Double wedge resection 1 (5.3) Segmentectomy 1 (5.3) Lobectomy 4 (21.0) Lymphadenectomy 5 (26.3) Complications 2 (10.5) Adjuvant CHT after pulmonary resection 6 (31.6) Recurrences 11 (57.9) DFI, disease-free interval; CHT, chemotherapy; VATS, videoassisted thoracoscopic surgery. tumor, presence of pulmonary symptoms. The aim of this study is to present our cohort of patients undergoing pulmonary metastasectomy for UM and to review the data reported in literature. Methods From January 1997 to December patients (mean age 61.2±12.1 years) underwent lung resection for metastatic uterine cancers at our Institution. Our institutional committee board approved this retrospective study. Demographic, clinical, pathological (Table 1) and survival data were retrospectively reviewed. The institutional board of our surgical department in all patients primary cancer was treated with complete surgical resection and five patients (26.3%) underwent adjuvant therapy with a platinum-based regimen. EA was the primary malignancy in 12 patients (63.2%), UL in 4 (21%), SCC in 2 (10.5%) and PSA in 1 (5.3%). All patients underwent preoperative work up including routine blood analysis, chest X-ray, cardiological evaluation with electrocardiogram and when required 2D echocardiography, pulmonary function tests and arterial blood gas analysis. Fifteen patients (79%) had serial total body computed tomography (CT) that documented the new presence of a pulmonary nodule, whereas in 4 (21%) positron emission tomography (PET) showed high uptake of a pulmonary lesion. In all patients but in 3 (16%) a solitary pulmonary nodule was present; in the others, 2 homolateral lesions were detected, in two cases in the same lobe and in 1 in different lobes. Only 1 patient (5.2%) showed symptoms as persistent cough and hemoptysis caused by a large central lesion. The diseasefree interval (DFI) was calculated from the gynecologic procedure to the detection of pulmonary recurrences; the median DFI was 35 months (range, months). In eight patients (42.1%) the DFI was less than 24 months. Survival was defined as interval from lung resection until death or last follow-up. Overall and disease-free survival curves were calculated with the Kaplan-Meier method. Chi-squared test or Fisher s exact test were used for univariate analysis and Cox proportional hazard regression to evaluate risk factors on survival. Variables showing a P value less/equal to 0.1 at univariate analysis were inserted in the multivariate analysis. P values less than 0.05 were considered statistically significant. All analyses were conducted with SPSS version Results All the procedures were pathologically R0 resections: 14 patients (78.9%) received a wedge resection (one patient with two nodules in different lobes underwent two wedge resections), 4 a lobectomy and 1 a segmentectomy. Video-assisted thoracoscopy (uniportal or biportal) was the surgical approach in 12 wedge resections and lateral thoracotomy in others. Mini-invasive approach was preferred in case of peripheral nodule. Indication for lobectomy was the diameter of the tumor in one patient, the hilar involvement in another and the presence of two nodules in the same lobe in the other two. Sampling of hilar and mediastinal nodal stations was performed during
3 Journal of Thoracic Disease, Vol 9, Suppl 12 October 2017 S1275 Table 2 Univariate analysis for survival Variables Number 5-year survival P Age < > FIGO stage I-II III-IV Adjuvant CHT after first surgery No Yes Histology EA Others DFI <24 months >24 months Recurrences No Yes CHT, chemotherapy; EA, endometrial adenocarcinoma; DFI, disease-free interval. lobectomy and segmentectomy and in 1 case positive hilar nodes were detected at histologic examination; no lymph nodes were removed in case of wedge resection. No perioperative deaths occurred and only two patients had minor complications (1 prolonged air leaks after lobectomy and 1 atelectasis requiring bronchoscopic toilette after segmentectomy). The median follow up after pulmonary metastasectomy was 54 months (range, months). Six patients (31.6%), including the four lobectomies, the segmentectomy and the double wedge resection patients received postoperative chemotherapy based on platinum regimen. Eleven patients (58%) showed recurrences: in 8 (72.7%) the disease was disseminated (more than one site), in 3 (27.3%) was present only in the treated lung; recurrent disease was treated with chemotherapy in eight cases and with supportive care alone in 3. After pulmonary metastasectomy overall 5- and 10-year survival was 40.9% and 31.4%, respectively. Five-year disease-free survival was 12.8% with a median Table 3 Multivariate analysis for survival Variables HR 95% CI P Adjuvant CHT after first surgery disease-free survival of 10 months. Patients treated with surgery and adjuvant therapy showed a better 5-year survival, although not achieving statistical significance (52.4% vs. 37.6%, P=0.08). Univariate analysis showed that DFI of less than 24 months (P=0.003), recurrence after pulmonary metastasectomy (P=0.02) and adjuvant therapy after initial gynecologic cancer (P=0.01) had a negative impact on survival (Table 2); at multivariate analysis only a DFI of less than 24 months and recurrence after pulmonary metastasectomy were negative factors for survival (P=0.002 and P=0.006, respectively) (Table 3). Discussion Histology DFI Recurrences HR, hazard ratio; CHT, chemotherapy; DFI, disease-free interval. It is by now clear that in selected patients pulmonary metastasectomy after previous gynecologic cancers is considered the gold standard with satisfactory results in terms of long term survival. The criteria for surgical treatment are (I) good performance status of patient, (II) controlled primary tumor, (III) no evidence of extrapulmonary disease and (IV) no other better therapy available. Surgery is certainly a viable option in case of metastatic lung disease (10-12). Several experiences reported in the literature showed a 5-year survival ranging from 32.9% to 48.2% (4-7) and our data are similar with a 5-year survival of 40.9%; however, quite surprisingly, in the paper published in 2015 Adachi et al. (13) reported that the 5-year overall survival among 23 patients was 81.7% albeit 10 of these patients (43.4%) experienced recurrences and three of them died for their disease. The authors explained these results with a better selection of patients (none patient had more than four nodules) and with the R0 resection in most of the patients. Different factors have been reported to have a prognostic impact on survival: histology, age, number of nodules, presence of symptoms, length of DFI from the primary tumor, recurrence after pulmonary metastasectomy, stage of the first tumor and need of
4 S1276 Anile et al. Pulmonary metastasectomy after gynecologic cancers adjuvant therapy after gynecologic surgery (4,5,7,8,13,14). We have assessed several variables: short DFI (less than 24 months) and recurrence after pulmonary metastasectomy were the only independent factors affecting long-term survival. In the literature it remains controversial the real impact of DFI on survival: some authors (15,16) reported that the interval between the gynecologic cancer and onset of lung metastases was not a prognostic factor. However, other studies (4,17), similarly to our results, showed that a longer DFI was associated with improvement of survival; since the DFI cut-off varied in the different studies ranging from less/more than 12 months to less/more than 36 months, we have considered as a balanced DFI cutoff less/more than 24 months. Although also Anraku et al. (7) reported the advantages of longer DFI, they highlighted that patients with a single metastasis and a DFI shorter than 12 months showed a 5-year survival of 48.6%. Thus they recommended to not preclude pulmonary resection in these patients. Furthermore, it is not clear what is the optimal number of lung metastases to remove with curative intent; although Girard et al. (18) reported a 5-year survival rate of 28% after metastasectomy of more than eight lesions (with no significant differences on survival with patients with less than eight nodules), in most of the studies no more than four nodules were removed and patients with less metastases showed constantly a better prognosis. Only in three cases (15.7%) we removed two nodules (two lobectomies and one double wedge resection), thus we are not able to add further information. Differently to other experiences (13,14), no patient in our series with recurrence after pulmonary resection underwent surgery again; they received chemotherapy or palliative care. Almost one third of our patients underwent adjuvant therapy with a platinum regimen after pulmonary metastasectomy showing a better 5-year survival rate respect to other patients. Five out of six of these patients (83.3%) received an anatomical resection (four lobectomies and one segmentectomy) and complete lymphadenectomy; this point could encourage a more aggressive in very selected patients treatment to improve the results, even if in our series the number of patients is limited and the differences in terms of survival are not statistically significant. In conclusion, our results confirm that pulmonary metastasectomy after gynecologic cancers is a safe and feasible procedure contributing to achieve long-term survival when the inclusion criteria are respected. In very selected patients a more aggressive approach with anatomical resection and adjuvant chemotherapy could allow better prognosis. Since just a few series are reported in the literature, it should be preferred to plan multicenter studies with tight inclusion criteria to enlarge the numbers and obtain more validated results. Acknowledgements None. Footnote Conflicts of Interest: The authors have no conflicts of interest to declare. Ethical Statement: Our institutional committee board approved this retrospective study. References 1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review , National Cancer Institute. Available online: 2. Ballon SC, Berman ML, Donaldson RC, et al. Pulmonary metastases of endometrial carcinoma. Gynecol Oncol 1979;7: Paik ES, Yoon A, Lee YY, et al. Pulmonary metastasectomy in uterine malignancy: outcomes and prognostic factors. J Gynecol Oncol 2015;26: Anderson TM, McMahon JJ, Nwogu CE, et al. Pulmonary resection in metastatic uterine and cervical malignancies. Gynecol Oncol 2001;83: Yamamoto K, Yoshikawa H, Shiromizu K, et al. Pulmonary metastasectomy for uterine cervical cancer: a multivariate analysis. Ann Thorac Surg 2004;77: van Nagell JR Jr, Rayburn W, Donaldson ES, et al. Therapeutic implications of patterns of recurrence in cancer of the uterine cervix. Cancer 1979;44: Anraku M, Yokoi K, Nakagawa K, et al. Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients. J Thorac Cardiovasc Surg 2004;127: Tirumani SH, Deaver P, Shinagare AB, et al. Metastatic pattern of uterine leiomyosarcoma: retrospective analysis of the predictors and outcome in 113 patients. J Gynecol Oncol 2014;25: Torek F. Removal of metastatic carcinoma of the lung and mediastinum: suggestions as to technique. Arch Surg 1930;21:
5 Journal of Thoracic Disease, Vol 9, Suppl 12 October 2017 S Internullo E, Cassivi SD, Van Raemdonck D, et al. Pulmonary metastasectomy: a survey of current practice amongst members of the European Society of Thoracic Surgeons. J Thorac Oncol 2008;3: Lin JC, Wiechmann RJ, Szwerc MF, et al. Diagnostic and therapeutic video-assisted thoracic surgery resection of pulmonary metastases. Surgery 1999;126:636-41; discussion De Giacomo T, Rendina EA, Venuta F, et al. Thoracoscopic resection of solitary lung metastases from colorectal cancer is a viable therapeutic option. Chest 1999;115: Adachi M, Mizuno M, Mitsui H, et al. The prognostic impact of pulmonary metastasectomy in recurrent gynecologic cancers: a retrospective single-institution study. Nagoya J Med Sci 2015;77: Clavero JM, Deschamps C, Cassivi SD, et al. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. Ann Thorac Surg 2006;81: Barter JF, Soong SJ, Hatch KD, et al. Diagnosis and treatment of pulmonary metastases from cervical carcinoma. Gynecol Oncol 1990;38: Seki M, Nakagawa K, Tsuchiya S, et al. Surgical treatment of pulmonary metastases from uterine cervical cancer. Operation method by lung tumor size. J Thorac Cardiovasc Surg 1992;104: Fuller AF Jr, Scannell JG, Wilkins EW Jr. Pulmonary resection for metastases from gynecologic cancers: Massachusetts General Hospital experience, Gynecol Oncol 1985;22: Girard P, Spaggiari L, Baldeyrou P, et al. Should the number of pulmonary metastases influence the surgical decision? Eur J Cardiothorac Surg 1997;12:385-91; discussion 392. Cite this article as: Anile M, Mantovani S, Pecoraro Y, Carillo C, Gherzi L, Pagini A, Rendina EA, Venuta F, Diso D. Pulmonary metastasectomy in uterine malignancies: outcome and prognostic factors. J Thorac Dis 2017;9(Suppl 12):S1273- S1277. doi: /jtd
After primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationUniportal video-assisted thoracoscopic surgery segmentectomy
Case Report on Thoracic Surgery Page 1 of 5 Uniportal video-assisted thoracoscopic surgery segmentectomy John K. C. Tam 1,2 1 Division of Thoracic Surgery, National University Heart Centre, Singapore;
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationPulmonary metastasectomy in uterine malignancy: outcomes and prognostic factors
Review Article Pulmonary metastasectomy in uterine malignancy: outcomes and prognostic factors Rocco Bilancia 1, Marco Nardini 2, David Waller 3 1 Department of Thoracic Surgery, Golden Jubilee National
More informationWhen a solitary pulmonary lesion (SPL) is found in
GENERAL THORACIC Resection of Solitary Pulmonary Lesion Is Beneficial to Patients With a History of Malignancy Miki Sakamoto, MD, Tomohiro Murakawa, MD, Kentaro Kitano, MD, Tomonori Murayama, MD, Takehiro
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationCASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003
CASE REPORT Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases, 18 and 15 years after nephrectomy Kosmas Tsakiridis 1, Aikaterini N Visouli
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationA Clinicopathological Review of Pulmonary Metastasis from Uterine Cervical Cancer
pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 216;48(1):266-272 Original Article http://dx.doi.org/1.4143/crt.214.26 Open Access A Clinicopathological Review of Pulmonary Metastasis from Uterine Cervical
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationValue of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy
Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationPulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationCheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda
Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationThe predictive accuracy of sentinel nodes mapping in the setting of pulmonary metastasectomy
DOI 10.1007/s10585-016-9834-6 RESEARCH PAPER The predictive accuracy of sentinel nodes mapping in the setting of pulmonary metastasectomy Hyun Koo Kim 1 Kwanghyoung Lee 2 Kook Nam Han 1 Jae Seon Eo 3 Sungeun
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationThe Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer
Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationClinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer
Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationReasons for conversion during VATS lobectomy: what happens with increased experience
Review Article on Thoracic Surgery Page 1 of 5 Reasons for conversion during VATS lobectomy: what happens with increased experience Dario Amore, Davide Di Natale, Roberto Scaramuzzi, Carlo Curcio Division
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationPulmonary resection for metastatic colorectal carcinoma was first performed
General Thoracic Surgery Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment Yukihito Saito, MD, a Hideyasu Omiya, MD, a Keijiro Kohno, MD, b Takanobu Kobayashi,
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationVideo-Mediastinoscopy Thoracoscopy (VATS)
Surgical techniques Video-Mediastinoscopy Thoracoscopy (VATS) Gunda Leschber Department of Thoracic Surgery ELK Berlin Chest Hospital, Berlin, Germany Teaching Hospital of Charité Universitätsmedizin Berlin
More informationPulmonary Resection for Metastases from Colorectal Cancer
ORIGINAL ARTICLE Pulmonary Resection for Metastases from Colorectal Cancer Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,* Bonne Biesma, MD, PhD, and Koop Bosscha, MD,
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationHistopathologic Prognostic Factors in Resected Colorectal Lung Metastases
Histopathologic Prognostic Factors in Resected Colorectal Lung Metastases Satoshi Shiono, MD, Genichiro Ishii, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, Yukinori Murata, MT, Koji Tsuta,
More informationOriginal Article Clinical predictors of lymph node metastasis in lung adenocarcinoma: an exploratory study
Int J Clin Exp Med 2016;9(5):8765-8769 www.ijcem.com /ISSN:1940-5901/IJCEM0017315 Original Article Clinical predictors of lymph node metastasis in lung adenocarcinoma: an exploratory study Zhijun Zhu,
More informationVATS Metastasectomy. Inderpal (Netu) S. Sarkaria, MD, FACS
VATS Metastasectomy Inderpal (Netu) S. Sarkaria, MD, FACS Vice Chairman, Clinical Affairs Director, Robotic Thoracic Surgery Co-Director, Esophageal and Lung Surgery Institute Disclosures Speaking & Education:
More informationSurgical treatment in non-small cell lung cancer with pulmonary oligometastasis
He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,
More informationVariability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival
Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival Mert Saynak, MD, Jessica Hubbs, MS, Jiho Nam, MD, Lawrence B. Marks, MD, Richard H. Feins, MD, Benjamin
More informationSurgical Approaches to Pulmonary Metastases
Surgical Approaches to Pulmonary Metastases Raja M Flores MD Professor and Chief Thoracic Surgery Mount Sinai School of Medicine New York, New York History of Lung Metastasectomy 1882 Weinlechner +CW 1926
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationThe prognostic importance of the number of metastases in pulmonary metastasectomy of colorectal cancer
Cho et al. World Journal of Surgical Oncology (2015) 13:222 DOI 10.1186/s12957-015-0621-7 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access The prognostic importance of the number of metastases in
More informationSurgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital
Surgical Management of Pulmonary Metastases Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital Introduction Lungs 2 nd most common site of metastatic deposition
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationInduction chemotherapy followed by surgical resection
Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationThymic neoplasms are the most common tumors of
Thymic Carcinoma: A Multivariate Analysis of Factors Predictive of Survival in 290 Patients Benny Weksler, MD, Rajeev Dhupar, MD, MBA, Vishal Parikh, BS, Katie S. Nason, MD, MPH, Arjun Pennathur, MD, and
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationIn the past, pulmonary metastases (PM) were considered
Original Article The Role of Extended Pulmonary Metastasectomy Monica Casiraghi, MD,* Patrick Maisonneuve, Eng, Daniela Brambilla, Msc,* Francesco Petrella, MD,* Piergiorgio Solli, MD,* Juliana Guarize,
More informationSurgical Treatment for Pulmonary Me. Tsunehisa; Kugimiya, Toshiyasu. Citation Acta medica Nagasakiensia. 1983, 28
NAOSITE: Nagasaki University's Ac Title Author(s) Surgical Treatment for Pulmonary Me Ayabe, Hiroyoshi; Tomita, Masao; Na Katsunobu; Nakao, Susumu; Eguchi, M Tsunehisa; Kugimiya, Toshiyasu Citation Acta
More informationSleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib
Case Report Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Ichiro Sakanoue 1, Hiroshi Hamakawa 1, Reiko Kaji 2, Yukihiro Imai 3, Nobuyuki Katakami 2, Yutaka Takahashi 1 1 Department
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationPredictive risk factors for lymph node metastasis in patients with resected nonsmall cell lung cancer: a case control study
Moulla et al. Journal of Cardiothoracic Surgery (2019) 14:11 https://doi.org/10.1186/s13019-019-0831-0 RESEARCH ARTICLE Open Access Predictive risk factors for lymph node metastasis in patients with resected
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationPredictors of unexpected nodal upstaging in patients with ct1-3n0 non-small cell lung cancer (NSCLC) submitted to thoracoscopic lobectomy
Original Article on Thoracic Surgery Page 1 of 10 Predictors of unexpected nodal upstaging in patients with ct1-3n0 non-small cell lung cancer (NSCLC) submitted to thoracoscopic lobectomy Giuseppe Marulli*,
More informationVideo-assisted thoracic surgery (VATS) for resection of metastatic adenocarcinoma as an acceptable alternative
Surg Endosc (2009) 23:1947 1954 DOI 10.1007/s00464-008-0243-z Video-assisted thoracic surgery (VATS) for resection of metastatic adenocarcinoma as an acceptable alternative Marilee Carballo Æ Mary S. Maish
More informationAdrenal glands are a common metastatic site for non small cell lung cancer
Surgical treatment of solitary adrenal metastasis from non small cell lung cancer Olaf Mercier, MD, Elie Fadel, MD, PhD, Marc de Perrot, MD, Sacha Mussot, MD, Franco Stella, MD, Alain Chapelier, MD, PhD,
More informationThe lungs are the second most frequent site for metastases
Prognostic Factors for Survival After Pulmonary Resection of Metastatic Renal Cell Carcinoma Joachim Pfannschmidt, MD, Hans Hoffmann, MD, PhD, Thomas Muley, PhD, Sabine Krysa, MD, Christine Trainer, MD,
More informationIs uniportal thoracoscopic surgery a feasible approach for advanced stages of non-small cell lung cancer?
Original rticle Is uniportal thoracoscopic surgery a feasible approach for advanced stages of non-small cell lung cancer? Diego Gonzalez-Rivas 1,2, Eva Fieira 1, Maria Delgado 1, Lucía Mendez 1, Ricardo
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationSurgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database
Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department
More informationUniportal video assisted thoracoscopy major lung resections after neoadjuvant chemotherapy
Original Article Uniportal video assisted thoracoscopy major lung resections after neoadjuvant chemotherapy Mahmoud Ismail 1, Dania Nachira 2, Marc Swierzy 1, Gian Maria Ferretti 2, Julianna Paulina Englisch
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationMore than half of the patients undergoing resection for colorectal
General Thoracic Surgery Pfannschmidt et al Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: Experiences in 167 patients Joachim Pfannschmidt,
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationUniportal video-assisted thoracic surgery for complicated pulmonary resections
Review Article on Thoracic Surgery Uniportal video-assisted thoracic surgery for complicated pulmonary resections Ding-Pei Han, Jie Xiang, Run-Sen Jin, Yan-Xia Hu, He-Cheng Li Jiaotong University School
More informationSmall cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationPrognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer
Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer Jagan Rao, FRCS(C-Th), Rana A. Sayeed, FRCS(C-Th), Sandra Tomaszek, Stefan Fischer, MD, Shaf Keshavjee, MD, FRCSC, and Gail
More informationLONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More informationUniportal video-assisted thoracoscopic surgery following neoadjuvant chemotherapy for locally-advanced lung cancer
Yang and Zhai Journal of Cardiothoracic Surgery (2018) 13:33 https://doi.org/10.1186/s13019-018-0714-9 RESEARCH ARTICLE Open Access Uniportal video-assisted thoracoscopic surgery following neoadjuvant
More informationPrognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule
Original Article Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule Jong Hui Suh 1, Jae Kil Park 2, Youngkyu Moon 2 1 Department of Thoracic & Cardiovascular Surgery,
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationA Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationRelevance of an extensive follow-up after surgery for nonsmall cell lung cancer
ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis
More informationSignificance of the lymph nodes in the 7th station in rational dissection for metastasis of distal gastric cancer with different T categories
Original Article Significance of the lymph nodes in the 7th station in rational dissection for metastasis of distal gastric cancer with different T categories Wu Song, Yulong He, Shaochuan Wang, Weiling
More informationROBOT SURGEY AND MINIMALLY INVASIVE TREATMENT FOR LUNG CANCER
ROBOT SURGEY AND MINIMALLY INVASIVE TREATMENT FOR LUNG CANCER Giulia Veronesi European Institute of Oncology Milan Lucerne, Samo 24 th - 25 th January, 2014 DIAGNOSTIC REVOLUTION FOR LUNG CANCER - Imaging
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationSurgical resection is the first treatment of choice for
Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationMetachronous pulmonary metastasis after radical esophagectomy for esophageal cancer: prognosis and outcome
Takemura et al. Journal of Cardiothoracic Surgery 2012, 7:103 RESEARCH ARTICLE Open Access Metachronous pulmonary metastasis after radical esophagectomy for esophageal cancer: prognosis and outcome Masashi
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More information